[July 30, 2014]

Research and Markets: Retinal Degeneration - Pipeline Review, H1 2014

Research and Markets (http://www.researchandmarkets.com/research/mqk5sw/retinal) has announced the addition of the "Retinal Degeneration - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects.

Drug profiles/records featured in the report undergo periodic udating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

• The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned:

• AmpliPhi Biosciences Corporation
• SanBio, Inc.
• to-BBB technologies BV
• Aprogen, Inc.
• X-BODY BioSciences, Inc.
• GenSight Biologics
• Spark Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/mqk5sw/retinal

[ Back To TMCnet.com's Homepage ]